MYGN Q1 2022 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$487M

Q1 2022 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$165M-4.7% YoY

Gross Profit

$117M70.9% margin

Operating Income

-$15M-9.0% margin

Net Income

-$21M-12.4% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

+2.5%

Cash Flow

Operating Cash Flow

-$47M

Free Cash Flow

-$53M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$305M

Stockholders' Equity

$950M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$165M	$173M	-4.7%
Gross Profit	$117M	$123M	-4.8%
Operating Income	-$15M	-$47M	+68.1%
Net Income	-$21M	-$40M	+48.1%

Geographic Segments

UNITED STATES

$20M61%

Non-US

$13M39%